Marker Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates

Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today reported corporate updates and financial results for the third quarter ended September 30, 2023.

“During the third quarter of 2023, we continued to diligently advance and execute our clinical objectives across our novel multiTAA-specific T cell pipeline,” commented Juan F. Vera, M.D., President and Chief Executive Officer of Marker Therapeutics. “Among the many highlights, we announced in September that we observed a complete response in the first patient with lymphoma treated with MT-601, our multiTAA-specific T cell product candidate targeting six antigens. This study participant was enrolled in our Phase 1 APOLLO trial after failing anti-CD19 CAR T cell therapy. The positive clinical outcome in this CAR T relapsed participant is supported by non-clinical proof-of-concept data and highlights the potential of MT-601 in patients who have relapsed after CAR T cell therapy. Together with the favorable clinical safety and tolerability profile, MT-601 may represent a suitable alternative for the treatment of patients with lymphoma.”

“In July, our MT-401 program was granted Orphan Drug Designation by the EMA for the treatment of patients with AML,” continued Dr. Vera. “We also reported non-clinical proof-of-concept data from our MT-401-OTS program, which indicated the potential anti-tumor activity of the product in a partially human leukocyte antigen (HLA) matched setting. With the clearance of our clinical protocol for MT-401-OTS from the U.S. FDA and the added validation from our non-clinical work, we anticipate initiating a clinical trial in 2024 to evaluate the potential of this novel therapy in patients with relapsed/refractory AML.”

“To maximize shareholder value and accelerate our patient-centric mission, we continue to engage in internal and external conversations with pertinent stakeholders to optimize our clinical development plan, which we expect to announce in the first quarter of 2024. With our healthy balance sheet and clinical progress shown to date, we believe we are well poised to achieve our near-and long-term growth objectives,” concluded Dr. Vera.

Program Updates and Expected Milestones:

MT-401 (Acute Myeloid Leukemia)

Marker was granted ODD from the Committee for Orphan Medicinal Products of the EMA for the treatment of patients with AML. This follows the ODD from U.S. FDA in 2020.
Marker reported non-clinical proof-of-concept data of MT-401 in an OTS setting and provided updates on clinical readiness for the MT-401-OTS program, which will investigate the treatment of patients with relapsed/refractory AML. Marker has established an inventory for MT-401-OTS and anticipates initial patient treatment in 2024.
Marker reported non-clinical data to bolster the clinical investigation of MT-401 after hypomethylating agent (HMA) administration and received a $2 million grant from the NIH Small Business Innovation Research (SBIR) program in support of the clinical study.

MT-601 (Lymphoma)

Complete response in the first patient with lymphoma treated with MT-601 in the Phase 1 multicenter APOLLO trial (clinicaltrials.gov identifier: NCT05798897) following participant’s failure to respond to four prior lines of therapy including anti-CD19 CAR T cell therapy. The study participant was treated with 2 doses of MT-601 at a 200 million cell dose level without prior lymphodepletion and showed no clinically significant treatment-related adverse events. At the first assessment, eight weeks after the second infusion of MT-601, the participant demonstrated a complete metabolic response based on PET-CT scans. MT-601 treatment was well tolerated with no treatment-related adverse events.
This clinical observation is supported by in vitro data demonstrating the anti-tumor activity of MT-601 in anti-CD19 CAR T resistant lymphoma cells, highlighting the therapeutic potential of MT-601.
Marker is treating and evaluating additional patients in the Phase 1 APOLLO trial and anticipates reporting additional data in the first half of 2024.

MT-601 (Pancreatic)

Investigational New Drug (IND) application cleared by U.S. FDA for multicenter Phase 1 trial of MT-601 in patients with metastatic pancreatic cancer in combination with first-line chemotherapy.
Clinical advancement will be pending additional financial support from non-dilutive grant activities.

Third Quarter 2023 Financial Highlights:

Cash Position: Cash and cash equivalents of $17.5 million at September 30, 2023.
R&D Expenses: Research and development expenses were $2.0 million for the quarter ended September 30, 2023, compared to $3.6 million for the quarter ended September 30, 2022. The decrease in R&D expenses was primarily attributable to lower expenses from the sale of Marker’s cell processing facility to Cell Ready, which was completed in June 2023.
G&A Expenses: General and administrative expenses were $1.4 million for the quarter ended September 30, 2023, compared to $3.2 million for the quarter ended September 30, 2022. The decrease in G&A expenses was also primarily attributable to the sale of Marker’s cell processing facility to Cell Ready.
Net Loss: Marker reported a net loss of ($3.0) million for the quarter ended September 30, 2023, compared to a net loss of ($6.9) million, inclusive of the $(1.2) million loss from discontinued operations, reflected in the quarter ended September 30, 2022.

About Marker Therapeutics, Inc.

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. The T cell therapy technology developed by Marker is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens (i.e., tumor targets) and kill tumor cells expressing those targets. This population of T cells is designed to attack multiple tumor targets following infusion into patients and to activate the patient’s immune system to produce broad spectrum anti-tumor activity. Because Marker does not genetically engineer the T cells, Marker believes that its product candidates will be easier and less expensive to manufacture, with reduced toxicities, compared to current engineered CAR T and TCR-based approaches, and may provide patients with meaningful clinical benefit. As a result, Marker believes its portfolio of T cell therapies has a compelling product profile, as compared to current gene-modified CAR T and TCR-based therapies.

To receive future press releases via email, please visit: HTTPS://WWW.MARKERTHERAPEUTICS.COM/EMAIL-ALERTS.

Forward-Looking Statements

This release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Statements in this news release concerning Marker’s expectations, plans, business outlook or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are “forward-looking statements.” Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: our research, development and regulatory activities and expectations relating to our non-engineered multi-tumor antigen specific T cell therapies; the effectiveness of these programs or the possible range of application and potential curative effects and safety in the treatment of diseases; the timing, conduct and success of our clinical trials of our product candidates, including MT-601 for the treatment of patients with lymphoma and MT-401 for the treatment of patients with AML; the potential benefits of orphan drug designation to MT401; and our future operating expenses and capital expenditure requirements, including our anticipated cash runway. Forward-looking statements are by their nature subject to risks, uncertainties and other factors which could cause actual results to differ materially from those stated in such statements. Such risks, uncertainties and factors include, but are not limited to the risks set forth in Marker’s most recent Form 10-K, 10-Q and other SEC filings which are available through EDGAR at WWW.SEC.GOV. Marker assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release except as may be required by law.

Marker Therapeutics, Inc.Condensed Consolidated Balance Sheets(Unaudited)

	September 30,			December 31,
		2023			2022
ASSETS
Current assets:
Cash and cash equivalents	$	17,473,899		$	11,782,172
Prepaid expenses and deposits		1,929,355			1,849,239
Other receivables		83,313			2,402,004
Current assets of discontinued operations		-			585,840
Total current assets		19,486,567			16,619,255
Non-current assets of discontinued operations		-			17,802,929
Total assets	$	19,486,567		$	34,422,184


LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable and accrued liabilities	$	2,304,019		$	2,521,193
Related party payable		367,915			-
Deferred revenue		107,530			-
Current liabilities of discontinued operations		-			5,260,616
Total current liabilities		2,779,464			7,781,809
Non-current liabilities of discontinued operations		-			7,039,338
Total liabilities		2,779,464			14,821,147

Stockholders' equity:
Preferred stock, $0.001 par value, 5 million shares authorized, 0 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively		-			-
Common stock, $0.001 par value, 30 million shares authorized, 8.8 million and 8.4 million shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively		8,888			8,406
Additional paid-in capital		450,181,012			447,641,680
Accumulated deficit		(433,482,797	)		(428,049,049	)
Total stockholders' equity		16,707,103			19,601,037
Total liabilities and stockholders' equity	$	19,486,567		$	34,422,184

Marker Therapeutics, Inc.Condensed Consolidated Statements of Operations(Unaudited)


	For the Three Months Ended						For the Nine Months Ended
	September 30,						September 30,
		2023			2022			2023			2022
Revenues:
Grant income	$	257,606		$	999,571		$	2,254,601		$	2,754,401
Total revenues		257,606			999,571			2,254,601			2,754,401
Operating expenses:
Research and development		2,044,980			3,591,897			7,799,472			9,786,138
General and administrative		1,412,672			3,234,133			6,098,716			9,720,598
Total operating expenses		3,457,652			6,826,030			13,898,188			19,506,736
Loss from operations		(3,200,046	)		(5,826,459	)		(11,643,587	)		(16,752,335	)
Other income (expenses):
Arbitration settlement		-			-			-			(118,880	)
Interest income		218,085			99,750			337,819			138,653
Loss from continuing operations		(2,981,961	)		(5,726,709	)		(11,305,768	)		(16,732,562	)
Discontinued operations:
Loss from discontinued operations, net of tax		-			(1,192,874	)		(2,922,406	)		(9,341,717	)
Gain on disposal of discontinued operations		-			-			8,794,426			-
Income (loss) from discontinued operations		-			(1,192,874	)		5,872,020			(9,341,717	)
Net loss	$	(2,981,961	)	$	(6,919,583	)	$	(5,433,748	)	$	(26,074,279	)

Net earnings (loss) per share:
Loss from continuing operations, basic and diluted	$	(0.34	)	$	(0.69	)	$	(1.29	)	$	(2.01	)
Income (loss) from discontinued operations, basic	$	-		$	(0.14	)	$	0.67		$	(1.12	)
Income (loss) from discontinued operations, diluted	$	-		$	(0.14	)	$	0.66		$	(1.12	)
Net loss per share	$	(0.34	)	$	(0.83	)	$	(0.62	)	$	(3.13	)

Weighted average number of common shares outstanding:
Basic		8,825,881			8,359,920			8,782,340			8,343,477
Diluted		8,825,881			8,359,920			8,834,512			8,343,477

Marker Therapeutics, Inc.Condensed Consolidated Statements of Cash Flows(Unaudited)

	For the Nine Months Ended
	September 30, 2023
		2023			2022
Cash Flows from Operating Activities:
Net loss	$	(5,433,748	)	$	(26,074,279	)
Less: gain (loss) from discontinued operations, net of tax		5,872,020			(9,341,717	)
Net loss from continuing operations		(11,305,768	)		(16,732,562	)
Reconciliation of net loss to net cash used in operating activities:
Stock-based compensation		714,899			2,921,765
Gain on lease termination		-			(278,681	)
Changes in operating assets and liabilities:
Prepaid expenses and deposits		(80,116	)		(204,222	)
Other receivables		2,318,691			(1,680,782	)
Accounts payable and accrued expenses		208,348			(289,148	)
Deferred revenue		107,530			(1,146,186	)
Net cash used in operating activities - continuing operations		(8,036,416	)		(17,409,816	)
Net cash used in operating activities - discontinued operations		(6,035,961	)		(3,256,915	)
Net cash used in operating activities		(14,072,377	)		(20,666,731	)
Cash Flows from Investing Activities:
Net cash provided by (used in) investing activities - discontinued operations		18,664,122			(4,817,794	)
Net cash provided by (used in) investing activities		18,664,122			(4,817,794	)
Cash Flows from Financing Activities:
Proceeds from issuance of common stock, net		1,014,640			63,573
Proceeds from stock options exercise		85,342			-
Net cash provided by financing activities		1,099,982			63,573
Net increase (decrease) in cash, cash equivalents and restricted cash		5,691,727			(25,420,952	)
Cash, cash equivalents and restricted cash at beginning of the period		11,782,172			43,497,331
Cash, cash equivalents and restricted cash at end of the period	$	17,473,899		$	18,076,379